Overview

Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

Status:
Unknown status

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 (10 mg, 25 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with T2DM with insufficient glycaemic control. Open-label arm: to estimate efficacy and safety of 25 mg BI 10773 in very poorly controlled patients (HbA1c > 10%)

Phase:

Phase 3

Details

Lead Sponsor:

Taipei Medical University WanFang Hospital

Treatments:

Empagliflozin
Metformin